Fatma ElBadrawy

Fatma ElBadrawy

Auto-generated profile, based on publicly available information

Fatma ElBadrawy

Faculty of Medicine, Misr University for Science and Technology, 6th of October City, Egypt

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2026 in ASIDE Internal Medicine
Verified
Journal Article
Open access
PDF file
DADalia Atef Abouda
Dalia Atef Abouda
EMElsayed S. Moubarak
Elsayed S. Moubarak
FEFatma ElBadrawy
Fatma ElBadrawy
MHMalak A. Hassan
Malak A. Hassan
MHMohamed Mohsen Helal
Mohamed Mohsen Helal
MEMohamed Elsaid‎
Mohamed Elsaid‎
Background: Hemophilia A and B are inherited bleeding disorders in which outcomes are shaped by factor levels, inhibitor development, inter-individual pharmacokinetics, and progressive joint disease. With the emergence of extended half-life therapies, non-factor therapies, and gene therapy, there is an increasing need for biomarkers to support diagnosis, risk stratification, treatment selection, and monitoring. Methods: We conducted a narrative review of English-language studies indexed in PubMed, Scopus, Web of Science, and Google Scholar (January 2000 to October 2025). We prioritized primary studies, trials, registries, and assay-validation reports on diagnostic, prognostic, predictive, or monitoring biomarkers in hemophilia A/B; guidelines were used for context. Results: Established biomarkers include FVIII/FIX activity assays, inhibitor testing (Bethesda/Nijmegen-modified), F8/F9 genotyping, and imaging-based joint assessment. Emerging candidates include global hemostasis assays (thrombin generation, viscoelastic testing), PK/PD metrics for prophylaxis individualization, and exploratory inflammatory/angiogenic and tissue-turnover markers linked to arthropathy. Conclusions: Evidence for biomarkers in hemophilia is heterogeneous, and many non-traditional markers remain exploratory; standardized assays and prospective multicenter validation with clinically meaningful endpoints are needed before routine adoption. Limitation: This narrative synthesis was conducted in English and did not include a formal risk-of-bias assessment.